Clinical Trial Update: Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2) [Phase 4]

View source ↗

Summary

Phase 4 randomized pharmacodynamic study evaluating escalation from standard-dose clopidogrel to low-dose prasugrel in patients undergoing PCI with high bleedin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)
• PRASUGREL (prasugrel)

Snippet

Sponsor: University of Florida | Conditions: Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI) | Phase 4 | Status: RECRUITING